DAFNA Capital Management’s ProQR Therapeutics PRQR Stock Holding History

DAFNA Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.85M	Sell	1,530,361 -37,200	-2%	-$61.3K	0.54%	36
2026 Q1	$2.54M	Hold	1,567,561	–	–	0.58%	38
2025 Q4	$3.17M	Hold	1,567,561	–	–	0.74%	37
2025 Q3	$3.34M	Hold	1,567,561	–	–	0.82%	30
2025 Q2	$3.2M	Hold	1,567,561	–	–	0.88%	27
2025 Q1	$2.08M	Hold	1,567,561	–	–	0.59%	36
2024 Q4	$4.15M	Buy	1,567,561 +661,979	+73%	+$2.1M	1.06%	25
2024 Q3	$1.65M	Hold	905,582	–	–	0.39%	52
2024 Q2	$1.5M	Hold	905,582	–	–	0.36%	49
2024 Q1	$2.07M	Sell	905,582 -35,000	-4%	-$74.8K	0.47%	43
2023 Q4	$1.86M	Hold	940,582	–	–	0.45%	43
2023 Q3	$1.22M	Hold	940,582	–	–	0.38%	51
2023 Q2	$1.52M	Hold	940,582	–	–	0.42%	45
2023 Q1	$2M	Buy	+940,582	New	+$2.88M	0.6%	40
2022 Q4	–	Sell	-649,383	Closed	-$483K	–	83
2022 Q3	$483K	Buy	+649,383	New	+$522K	0.13%	71
2022 Q1	–	Sell	-85,476	Closed	-$685K	–	97
2021 Q4	$685K	Sell	85,476 -210,907	-71%	-$1.61M	0.17%	75
2021 Q3	$2.48M	Sell	296,383 -735,497	-71%	-$4.81M	0.66%	40
2021 Q2	$6.96M	Sell	1,031,880 -68,120	-6%	-$439K	1.45%	18
2021 Q1	$7.27M	Sell	1,100,000 -137,400	-11%	-$702K	1.73%	13
2020 Q4	$5.2M	Hold	1,237,400	–	–	1.55%	15
2020 Q3	$5.93M	Hold	1,237,400	–	–	1.93%	13
2020 Q2	$7.52M	Hold	1,237,400	–	–	2.17%	11
2020 Q1	$6.79M	Buy	1,237,400 +123,400	+11%	+$947K	2.83%	10
2019 Q4	$11M	Buy	1,114,000 +852,479	+326%	+$6.64M	3.79%	2
2019 Q3	$1.51M	Hold	261,521	–	–	0.57%	45
2019 Q2	$2.38M	Hold	261,521	–	–	0.89%	31
2019 Q1	$3.63M	Sell	261,521 -10,953	-4%	-$164K	1.56%	22
2018 Q4	$4.3M	Buy	272,474 +12,138	+5%	+$223K	2.14%	12
2018 Q3	$5.04M	Buy	260,336 +88,985	+52%	+$946K	2.07%	14
2018 Q2	$1.25M	Sell	171,351 -59,419	-26%	-$300K	0.59%	45
2018 Q1	$710K	Hold	230,770	–	–	0.35%	54
2017 Q4	$744K	Buy	+230,770	New	+$829K	0.4%	53

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

DAFNA Capital Management's PRQR Position: Q2 2026 in Review

DAFNA Capital Management reduced its ProQR Therapeutics (PRQR) stake by 2.4% in Q2 2026, selling an estimated $61.3K and leaving 1,530,361 shares worth $2.85M. The position accounts for 0.54% of the portfolio, ranked #36.

DAFNA Capital Management first reported a position in PRQR in Q4 2017 and has held it in 32 quarters since. The position peaked at $11M in Q4 2019. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

DAFNA Capital Management held 1,530,361 shares of ProQR Therapeutics worth $2.85M as of Q2 2026.
DAFNA Capital Management sold 37,200 ProQR Therapeutics shares in Q2 2026, an estimated $61.3K.
ProQR Therapeutics made up 0.54% of DAFNA Capital Management's portfolio in Q2 2026, its #36 holding.
DAFNA Capital Management first reported a position in ProQR Therapeutics in Q4 2017 and has held it in 32 quarters since.
DAFNA Capital Management's ProQR Therapeutics position peaked at $11M in Q4 2019.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.